148 related articles for article (PubMed ID: 8546392)
21. In vivo protective anti-HIV immune responses in non-human primates through DNA immunization.
Boyer JD; Wang B; Ugen KE; Agadjanyan M; Javadian A; Frost P; Dang K; Carrano RA; Ciccarelli R; Coney L; Williams WV; Weiner DB
J Med Primatol; 1996 Jun; 25(3):242-50. PubMed ID: 8892046
[TBL] [Abstract][Full Text] [Related]
22. Induction of anti-HIV-1 immune responses by retroviral vectors.
Jolly DJ; Warner JF
Biotechnol Ther; 1991; 2(1-2):179-93. PubMed ID: 1845120
[TBL] [Abstract][Full Text] [Related]
23. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.
Pincus SH; Messer KG; Schwartz DH; Lewis GK; Graham BS; Blattner WA; Fisher G
J Clin Invest; 1993 May; 91(5):1987-96. PubMed ID: 7683694
[TBL] [Abstract][Full Text] [Related]
24. An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes.
Stanhope PE; Liu AY; Pavlat W; Pitha PM; Clements ML; Siliciano RF
J Immunol; 1993 May; 150(10):4672-86. PubMed ID: 8097759
[TBL] [Abstract][Full Text] [Related]
25. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine.
Wu JY; Gardner BH; Murphy CI; Seals JR; Kensil CR; Recchia J; Beltz GA; Newman GW; Newman MJ
J Immunol; 1992 Mar; 148(5):1519-25. PubMed ID: 1538134
[TBL] [Abstract][Full Text] [Related]
26. A 2-year follow-up of an anti-HIV immune reaction in HIV-1 gp160-immunized healthy seronegative humans: evidence for persistent cell-mediated immunity.
Picard O; Achour A; Bernard J; Halbreich A; Bizzini B; Boyer V; Desgranges C; Bertho JM; Lachgar A; Polliotti B
J Acquir Immune Defic Syndr (1988); 1992; 5(6):539-46. PubMed ID: 1588488
[TBL] [Abstract][Full Text] [Related]
27. Gene inoculation generates immune responses against human immunodeficiency virus type 1.
Wang B; Ugen KE; Srikantan V; Agadjanyan MG; Dang K; Refaeli Y; Sato AI; Boyer J; Williams WV; Weiner DB
Proc Natl Acad Sci U S A; 1993 May; 90(9):4156-60. PubMed ID: 8483929
[TBL] [Abstract][Full Text] [Related]
28. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP
J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
[TBL] [Abstract][Full Text] [Related]
29. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.
Perales MA; Schwartz DH; Fabry JA; Lieberman J
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):27-35. PubMed ID: 7648281
[TBL] [Abstract][Full Text] [Related]
30. Polyvalent, recombinant HIV-1 virus-like particles: novel HIV-1 vaccine strategies.
Wagner R; Deml L; Wolf H
Antibiot Chemother (1971); 1994; 46():48-61. PubMed ID: 7826039
[No Abstract] [Full Text] [Related]
31. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses.
Sakaue G; Hiroi T; Nakagawa Y; Someya K; Iwatani K; Sawa Y; Takahashi H; Honda M; Kunisawa J; Kiyono H
J Immunol; 2003 Jan; 170(1):495-502. PubMed ID: 12496436
[TBL] [Abstract][Full Text] [Related]
32. Induction of HIV type 1 neutralizing and env-CD4 blocking antibodies by immunization with genetically engineered HIV type 1-like particles containing unprocessed gp160 glycoproteins.
Rovinski B; Rodrigues L; Cao SX; Yao FL; McGuinness U; Sia C; Cates G; Zolla-Pazner S; Karwowska S; Matthews TJ
AIDS Res Hum Retroviruses; 1995 Oct; 11(10):1187-95. PubMed ID: 8573374
[TBL] [Abstract][Full Text] [Related]
33. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
AIDS Vaccine Evaluation Group 022 Protocol Team
J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of cytotoxic T cell responses to candidate HIV-1 vaccines in HIV-1-uninfected individuals.
McElrath MJ; Corey L; Greenberg PD
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S69-72. PubMed ID: 7865336
[TBL] [Abstract][Full Text] [Related]
35. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immun 1994;98:178-84.
DePalma L
Pediatr AIDS HIV Infect; 1995 Apr; 6(2):97-8. PubMed ID: 11361387
[No Abstract] [Full Text] [Related]
36. Chimeras between the human immunodeficiency virus (HIV-1) Env and vaccinia virus immunogenic proteins p14 and p39 generate in mice broadly reactive antibodies and specific activation of CD8+ T cell responses to Env.
Collado M; Rodríguez D; Rodríguez JR; Vázquez I; Gonzalo RM; Esteban M
Vaccine; 2000 Jul; 18(27):3123-33. PubMed ID: 10856792
[TBL] [Abstract][Full Text] [Related]
37. Cross-neutralizing antibodies to HIV-1 in mice after immunization with gp160 iscoms. Dissection of the immune response.
Akerblom L; Nara P; Dunlop N; Morein B
AIDS Res Hum Retroviruses; 1991 Jul; 7(7):621-7. PubMed ID: 1768464
[TBL] [Abstract][Full Text] [Related]
38. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques.
Abimiku AG; Franchini G; Tartaglia J; Aldrich K; Myagkikh M; Markham PD; Chong P; Klein M; Kieny MP; Paoletti E
Nat Med; 1995 Apr; 1(4):321-9. PubMed ID: 7585061
[TBL] [Abstract][Full Text] [Related]
39. Clonal analysis of T-cell responses to the HIV-1 envelope proteins in AIDS vaccine recipients.
Siliciano RF; Bollinger RC; Callahan KM; Hammond SA; Liu AY; Miskovsky EP; Rowell JF; Stanhope PE
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1349-52. PubMed ID: 1361352
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of antibody responses to an HIV-2 DNA envelope vaccine using an expression vector containing a constitutive transport element.
Locher CP; Witt SA; Ashlock BM; Levy JA
DNA Cell Biol; 2002 Aug; 21(8):581-6. PubMed ID: 12215261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
